Key facts
- This page summarizes Douglas B. Given's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 18 Dec 2024, 18:18.
Douglas B. Given - 16 Dec 2024 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Reporting relationship
- Director
- Issuer ticker
- ARWR
- Reported as of
- 16 Dec 2024
- Net transaction value
- -$121,556
- SEC form
- 4
- Accepted by SEC
- 18 Dec 2024, 18:18:48 UTC
- Prior SEC filing
- 16 Jan 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Douglass Given
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Douglas B. Given filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 18 Dec 2024.
Change
- Previous filing in this sequence was filed on 16 Jan 2024.
- Current net transaction value: -$121,556.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARWR
transaction
Common Stock
Sale
- Transaction value
- $109,500
- Shares
- -5,000
- Change %
- -3.9%
- Price
- $21.90
- Shares after
- 124,714
- Date
- 16 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3, F4
ARWR
transaction
Common Stock
Sale
- Transaction value
- $12,056
- Shares
- -547
- Change %
- -0.44%
- Price
- $22.04
- Shares after
- 124,167
- Date
- 17 Dec 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Explanation of responses 4 footnotes
Footnote F1
Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
Footnote F2
Partial disposition of RSUs to satisfy tax withholding obligations.
Footnote F3
The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $21.64 to $22.20, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Footnote F4
Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions.